<DOC>
	<DOC>NCT01632306</DOC>
	<brief_summary>Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.</brief_summary>
	<brief_title>A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Metastatic pancreatic cancer with metastases amenable to biopsy Willingness to provide tissue and blood samples for research purposes Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 History of islet cell, acinar cell, or cystadenocarcinomas Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin) Radiation therapy, immunotherapy or biologic therapy &lt;28 days prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>